vs

Side-by-side financial comparison of Green Plains Inc. (GPRE) and Health Catalyst, Inc. (HCAT). Click either name above to swap in a different company.

Health Catalyst, Inc. is the larger business by last-quarter revenue ($74.7M vs $42.2M, roughly 1.8× Green Plains Inc.). Green Plains Inc. runs the higher net margin — 28.3% vs -121.9%, a 150.2% gap on every dollar of revenue. On growth, Green Plains Inc. posted the faster year-over-year revenue change (2.4% vs -6.2%). Green Plains Inc. produced more free cash flow last quarter ($62.0M vs $9.6M). Over the past eight quarters, Green Plains Inc.'s revenue compounded faster (0.8% CAGR vs -0.0%).

Green Plains Inc. is an American company based in Omaha, Nebraska that was founded in 2004. The company is the third largest ethanol fuel producer in North America. It was reported in early 2012 that the company ships approximately one billion gallons of ethanol per year. The company employs approximately 640 people, and was founded by Barry Ellsworth. Green Plains Inc. is listed on the NASDAQ Stock Exchange as GPRE.

Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company based in Coral Gables, Florida, United States. The company develops medicines for rare diseases, including the phosphate salt of amifampridine for the treatment of Lambert–Eaton myasthenic syndrome (LEMS). The drug is referred to under the trade name Firdapse, which was approved by the FDA for approved use in children 6 years and older with LEMS in addition to the prior approval for use in adults with LEMS on November 28, 2018. Fir...

GPRE vs HCAT — Head-to-Head

Bigger by revenue
HCAT
HCAT
1.8× larger
HCAT
$74.7M
$42.2M
GPRE
Growing faster (revenue YoY)
GPRE
GPRE
+8.6% gap
GPRE
2.4%
-6.2%
HCAT
Higher net margin
GPRE
GPRE
150.2% more per $
GPRE
28.3%
-121.9%
HCAT
More free cash flow
GPRE
GPRE
$52.4M more FCF
GPRE
$62.0M
$9.6M
HCAT
Faster 2-yr revenue CAGR
GPRE
GPRE
Annualised
GPRE
0.8%
-0.0%
HCAT

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
GPRE
GPRE
HCAT
HCAT
Revenue
$42.2M
$74.7M
Net Profit
$11.9M
$-91.0M
Gross Margin
95.1%
Operating Margin
-24.9%
-115.3%
Net Margin
28.3%
-121.9%
Revenue YoY
2.4%
-6.2%
Net Profit YoY
121.7%
-340.3%
EPS (diluted)
$0.26
$-1.29

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
GPRE
GPRE
HCAT
HCAT
Q4 25
$42.2M
$74.7M
Q3 25
$44.7M
$76.3M
Q2 25
$66.2M
$80.7M
Q1 25
$35.8M
$79.4M
Q4 24
$41.2M
$79.6M
Q3 24
$39.1M
$76.4M
Q2 24
$41.1M
$75.9M
Q1 24
$41.6M
$74.7M
Net Profit
GPRE
GPRE
HCAT
HCAT
Q4 25
$11.9M
$-91.0M
Q3 25
$11.9M
$-22.2M
Q2 25
$-72.2M
$-41.0M
Q1 25
$-72.9M
$-23.7M
Q4 24
$-54.9M
$-20.7M
Q3 24
$48.2M
$-14.7M
Q2 24
$-24.4M
$-13.5M
Q1 24
$-51.4M
$-20.6M
Gross Margin
GPRE
GPRE
HCAT
HCAT
Q4 25
95.1%
Q3 25
52.6%
Q2 25
62.8%
Q1 25
8.5%
Q4 24
14.9%
Q3 24
47.5%
Q2 24
92.0%
Q1 24
20.1%
Operating Margin
GPRE
GPRE
HCAT
HCAT
Q4 25
-24.9%
-115.3%
Q3 25
75.7%
-22.9%
Q2 25
-42.9%
-46.0%
Q1 25
-173.7%
-25.4%
Q4 24
-99.2%
-22.0%
Q3 24
-17.9%
Q2 24
-43.1%
-20.8%
Q1 24
-108.0%
-30.5%
Net Margin
GPRE
GPRE
HCAT
HCAT
Q4 25
28.3%
-121.9%
Q3 25
26.7%
-29.1%
Q2 25
-109.1%
-50.8%
Q1 25
-203.4%
-29.9%
Q4 24
-133.2%
-26.0%
Q3 24
123.4%
-19.3%
Q2 24
-59.2%
-17.8%
Q1 24
-123.7%
-27.6%
EPS (diluted)
GPRE
GPRE
HCAT
HCAT
Q4 25
$0.26
$-1.29
Q3 25
$0.17
$-0.32
Q2 25
$-1.09
$-0.59
Q1 25
$-1.14
$-0.35
Q4 24
$-0.79
$-0.33
Q3 24
$0.69
$-0.24
Q2 24
$-0.38
$-0.23
Q1 24
$-0.81
$-0.35

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
GPRE
GPRE
HCAT
HCAT
Cash + ST InvestmentsLiquidity on hand
$182.3M
$95.7M
Total DebtLower is stronger
$374.5M
$153.3M
Stockholders' EquityBook value
$766.2M
$245.8M
Total Assets
$1.6B
$502.6M
Debt / EquityLower = less leverage
0.49×
0.62×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
GPRE
GPRE
HCAT
HCAT
Q4 25
$182.3M
$95.7M
Q3 25
$135.9M
$91.5M
Q2 25
$108.6M
$97.3M
Q1 25
$98.6M
$342.0M
Q4 24
$173.0M
$392.0M
Q3 24
$227.5M
$387.3M
Q2 24
$195.6M
$308.3M
Q1 24
$237.3M
$327.8M
Total Debt
GPRE
GPRE
HCAT
HCAT
Q4 25
$374.5M
$153.3M
Q3 25
$153.1M
Q2 25
$153.0M
Q1 25
$382.9M
Q4 24
$437.8M
$382.4M
Q3 24
$345.0M
Q2 24
Q1 24
Stockholders' Equity
GPRE
GPRE
HCAT
HCAT
Q4 25
$766.2M
$245.8M
Q3 25
$768.9M
$331.9M
Q2 25
$735.2M
$347.5M
Q1 25
$797.5M
$376.8M
Q4 24
$865.2M
$365.2M
Q3 24
$925.5M
$355.0M
Q2 24
$867.4M
$357.0M
Q1 24
$887.5M
$357.2M
Total Assets
GPRE
GPRE
HCAT
HCAT
Q4 25
$1.6B
$502.6M
Q3 25
$1.5B
$587.1M
Q2 25
$1.6B
$616.2M
Q1 25
$1.7B
$891.5M
Q4 24
$1.8B
$858.9M
Q3 24
$1.8B
$813.0M
Q2 24
$1.8B
$691.7M
Q1 24
$1.8B
$695.1M
Debt / Equity
GPRE
GPRE
HCAT
HCAT
Q4 25
0.49×
0.62×
Q3 25
0.46×
Q2 25
0.44×
Q1 25
1.02×
Q4 24
0.51×
1.05×
Q3 24
0.97×
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
GPRE
GPRE
HCAT
HCAT
Operating Cash FlowLast quarter
$67.3M
$9.9M
Free Cash FlowOCF − Capex
$62.0M
$9.6M
FCF MarginFCF / Revenue
146.9%
12.9%
Capex IntensityCapex / Revenue
12.6%
0.4%
Cash ConversionOCF / Net Profit
5.64×
TTM Free Cash FlowTrailing 4 quarters
$73.7M
$-697.0K

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
GPRE
GPRE
HCAT
HCAT
Q4 25
$67.3M
$9.9M
Q3 25
$39.8M
$-464.0K
Q2 25
$58.8M
$-9.0M
Q1 25
$-55.0M
$280.0K
Q4 24
$-27.0M
$-3.5M
Q3 24
$62.7M
$6.2M
Q2 24
$-15.1M
$1.6M
Q1 24
$-50.6M
$10.3M
Free Cash Flow
GPRE
GPRE
HCAT
HCAT
Q4 25
$62.0M
$9.6M
Q3 25
$35.8M
$-719.0K
Q2 25
$47.7M
$-9.2M
Q1 25
$-71.8M
$-390.0K
Q4 24
$-54.2M
$-3.9M
Q3 24
$34.4M
$5.5M
Q2 24
$-32.8M
$1.3M
Q1 24
$-72.4M
$10.1M
FCF Margin
GPRE
GPRE
HCAT
HCAT
Q4 25
146.9%
12.9%
Q3 25
79.9%
-0.9%
Q2 25
72.0%
-11.4%
Q1 25
-200.2%
-0.5%
Q4 24
-131.5%
-4.9%
Q3 24
88.0%
7.2%
Q2 24
-79.8%
1.7%
Q1 24
-174.2%
13.5%
Capex Intensity
GPRE
GPRE
HCAT
HCAT
Q4 25
12.6%
0.4%
Q3 25
9.0%
0.3%
Q2 25
16.8%
0.3%
Q1 25
46.6%
0.8%
Q4 24
66.1%
0.5%
Q3 24
72.6%
0.9%
Q2 24
43.0%
0.4%
Q1 24
52.4%
0.3%
Cash Conversion
GPRE
GPRE
HCAT
HCAT
Q4 25
5.64×
Q3 25
3.33×
Q2 25
Q1 25
Q4 24
Q3 24
1.30×
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

GPRE
GPRE

Products And Services Other$26.6M63%
Distiller Grains$15.0M36%
Agribusiness And Energy Services$667.0K2%

HCAT
HCAT

Recurring Technology$51.9M69%
Professional Services$22.8M31%

Related Comparisons